12 Citazioni (Scopus)

Abstract

Breast cancer is the most frequent carcinoma and second most common cause of cancer-related mortality in postmenopausal women. The acquisition of somatic mutations represents the main mechanism through which cancer cells overcome physiological cellular signaling pathways (e.g., PI3K/Akt/mTOR, PTEN, TP53). To date, diagnosis and metastasis monitoring is mainly carried out through tissue biopsy and/or re-biopsy, a very invasive procedure limited only to certain locations and not always feasible in clinical practice. In order to improve disease monitoring over time and to avoid painful procedure such as tissue biopsy, liquid biopsy may represent a new precious tool. Indeed, it represents a basin of “new generation” biomarkers that are spread into the bloodstream from both primary and metastatic sites. Moreover, elevated concentrations of circulating tumor DNA (ctDNA) as well as circulating tumor cells (CTCs) have been found in blood plasma of patients with various tumor types. Nowadays, several new approaches have been introduced for the detection and characterization of CTCs and ctDNA, allowing a real-time monitoring of tumor evolution. This review is focused on the clinical relevance of liquid biopsy in breast cancer and will provide an update concerning CTCs and ctDNA utility as a tool for breast cancer patient monitoring during the course of disease.
Lingua originaleEnglish
pagine (da-a)1-11
Numero di pagine11
RivistaTumor Biology
Stato di pubblicazionePublished - 2016

Fingerprint

Breast Neoplasms
Biopsy
Circulating Neoplastic Cells
Neoplasms
DNA
Physiologic Monitoring
Phosphatidylinositol 3-Kinases
Biomarkers
Neoplasm Metastasis
Carcinoma
Mutation
Mortality

All Science Journal Classification (ASJC) codes

  • Cancer Research

Cita questo

@article{5bce51642d744bbcbaa7711a5fc832c9,
title = "A headlight on liquid biopsies: a challenging tool for breast cancer management",
abstract = "Breast cancer is the most frequent carcinoma and second most common cause of cancer-related mortality in postmenopausal women. The acquisition of somatic mutations represents the main mechanism through which cancer cells overcome physiological cellular signaling pathways (e.g., PI3K/Akt/mTOR, PTEN, TP53). To date, diagnosis and metastasis monitoring is mainly carried out through tissue biopsy and/or re-biopsy, a very invasive procedure limited only to certain locations and not always feasible in clinical practice. In order to improve disease monitoring over time and to avoid painful procedure such as tissue biopsy, liquid biopsy may represent a new precious tool. Indeed, it represents a basin of “new generation” biomarkers that are spread into the bloodstream from both primary and metastatic sites. Moreover, elevated concentrations of circulating tumor DNA (ctDNA) as well as circulating tumor cells (CTCs) have been found in blood plasma of patients with various tumor types. Nowadays, several new approaches have been introduced for the detection and characterization of CTCs and ctDNA, allowing a real-time monitoring of tumor evolution. This review is focused on the clinical relevance of liquid biopsy in breast cancer and will provide an update concerning CTCs and ctDNA utility as a tool for breast cancer patient monitoring during the course of disease.",
author = "Daniele Fanale and Nadia Barraco and Daniela Massihnia and Giuseppe Cicero and Valentina Calo' and Viviana Bazan and Alessandro Perez and Marta Castiglia and Antonina Cangemi and Giuseppe Bronte and Gianni Pantuso and Antonio Russo and {Di Piazza}, Florinda and Sergio Rizzo",
year = "2016",
language = "English",
pages = "1--11",
journal = "Tumor Biology",
issn = "1010-4283",
publisher = "Springer Netherlands",

}

TY - JOUR

T1 - A headlight on liquid biopsies: a challenging tool for breast cancer management

AU - Fanale, Daniele

AU - Barraco, Nadia

AU - Massihnia, Daniela

AU - Cicero, Giuseppe

AU - Calo', Valentina

AU - Bazan, Viviana

AU - Perez, Alessandro

AU - Castiglia, Marta

AU - Cangemi, Antonina

AU - Bronte, Giuseppe

AU - Pantuso, Gianni

AU - Russo, Antonio

AU - Di Piazza, Florinda

AU - Rizzo, Sergio

PY - 2016

Y1 - 2016

N2 - Breast cancer is the most frequent carcinoma and second most common cause of cancer-related mortality in postmenopausal women. The acquisition of somatic mutations represents the main mechanism through which cancer cells overcome physiological cellular signaling pathways (e.g., PI3K/Akt/mTOR, PTEN, TP53). To date, diagnosis and metastasis monitoring is mainly carried out through tissue biopsy and/or re-biopsy, a very invasive procedure limited only to certain locations and not always feasible in clinical practice. In order to improve disease monitoring over time and to avoid painful procedure such as tissue biopsy, liquid biopsy may represent a new precious tool. Indeed, it represents a basin of “new generation” biomarkers that are spread into the bloodstream from both primary and metastatic sites. Moreover, elevated concentrations of circulating tumor DNA (ctDNA) as well as circulating tumor cells (CTCs) have been found in blood plasma of patients with various tumor types. Nowadays, several new approaches have been introduced for the detection and characterization of CTCs and ctDNA, allowing a real-time monitoring of tumor evolution. This review is focused on the clinical relevance of liquid biopsy in breast cancer and will provide an update concerning CTCs and ctDNA utility as a tool for breast cancer patient monitoring during the course of disease.

AB - Breast cancer is the most frequent carcinoma and second most common cause of cancer-related mortality in postmenopausal women. The acquisition of somatic mutations represents the main mechanism through which cancer cells overcome physiological cellular signaling pathways (e.g., PI3K/Akt/mTOR, PTEN, TP53). To date, diagnosis and metastasis monitoring is mainly carried out through tissue biopsy and/or re-biopsy, a very invasive procedure limited only to certain locations and not always feasible in clinical practice. In order to improve disease monitoring over time and to avoid painful procedure such as tissue biopsy, liquid biopsy may represent a new precious tool. Indeed, it represents a basin of “new generation” biomarkers that are spread into the bloodstream from both primary and metastatic sites. Moreover, elevated concentrations of circulating tumor DNA (ctDNA) as well as circulating tumor cells (CTCs) have been found in blood plasma of patients with various tumor types. Nowadays, several new approaches have been introduced for the detection and characterization of CTCs and ctDNA, allowing a real-time monitoring of tumor evolution. This review is focused on the clinical relevance of liquid biopsy in breast cancer and will provide an update concerning CTCs and ctDNA utility as a tool for breast cancer patient monitoring during the course of disease.

UR - http://hdl.handle.net/10447/176221

UR - http://www.springer.com/biomed/cancer/journal/13277

M3 - Article

SP - 1

EP - 11

JO - Tumor Biology

JF - Tumor Biology

SN - 1010-4283

ER -